Insurance holding company Globe Life (NYSE: GL) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 5.4% year on year to $1.56 billion. Its GAAP profit of $3.39 per share was 2% below analysts’ consensus estimates.
Is now the time to buy Globe Life? Find out by accessing our full research report, it’s free.
Globe Life (GL) Q1 CY2026 Highlights:
- Net Premiums Earned: $1.27 billion vs analyst estimates of $1.28 billion (5.9% year-on-year growth, 0.6% miss)
- Revenue: $1.56 billion vs analyst estimates of $1.57 billion (5.4% year-on-year growth, in line)
- Pre-tax Profit: $334.1 million (21.4% margin)
- EPS (GAAP): $3.39 vs analyst expectations of $3.46 (2% miss)
- Book Value per Share: $77.03 vs analyst estimates of $99.58 (17.7% year-on-year growth, 22.6% miss)
- Market Capitalization: $11.84 billion
Company Overview
With roots dating back to 1900 and a rebranding from Torchmark Corporation in 2019, Globe Life (NYSE: GL) is an insurance holding company that offers life insurance, supplemental health insurance, and annuity products through various distribution channels.
Revenue Growth
In general, insurance companies earn revenue from three primary sources. The first is the core insurance business itself, often called underwriting and represented in the income statement as premiums earned. The second source is investment income from investing the “float” (premiums collected upfront not yet paid out as claims) in assets such as fixed-income assets and equities. The third is fees from various sources such as policy administration, annuities, or other value-added services. Unfortunately, Globe Life’s 4.8% annualized revenue growth over the last five years was tepid. This was below our standard for the insurance sector and is a tough starting point for our analysis.
We at StockStory place the most emphasis on long-term growth, but within financials, a half-decade historical view may miss recent interest rate changes, market returns, and industry trends. Globe Life’s annualized revenue growth of 4.5% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak. 
This quarter, Globe Life grew its revenue by 5.4% year on year, and its $1.56 billion of revenue was in line with Wall Street’s estimates.
Net premiums earned made up 81% of the company’s total revenue during the last five years, meaning Globe Life barely relies on non-insurance activities to drive its overall growth.
While insurers generate revenue from multiple sources, investors view net premiums earned as the cornerstone - its direct link to core operations stands in sharp contrast to the unpredictability of investment returns and fees.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
Book Value Per Share (BVPS)
Insurance companies are balance sheet businesses, collecting premiums upfront and paying out claims over time. The float–premiums collected but not yet paid out–are invested, creating an asset base supported by a liability structure. Book value per share (BVPS) captures this dynamic by measuring these assets (investment portfolio, cash, reinsurance recoverables) less liabilities (claim reserves, debt, future policy benefits). BVPS is essentially the residual value for shareholders.
We therefore consider BVPS very important to track for insurers and a metric that sheds light on business quality because it reflects long-term capital growth and is harder to manipulate than more commonly-used metrics like EPS.
Globe Life’s BVPS was flat over the last five years. However, BVPS growth has accelerated recently, growing by 19.9% annually over the last two years from $53.56 to $77.03 per share.
Over the next 12 months, Consensus estimates call for Globe Life’s BVPS to grow by 44.4% to $99.58, elite growth rate.
Key Takeaways from Globe Life’s Q1 Results
We struggled to find many positives in these results. Its book value per share missed and its EPS fell short of Wall Street’s estimates. Overall, this was a weaker quarter. The stock remained flat at $151.29 immediately after reporting.
Is Globe Life an attractive investment opportunity at the current price? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).
